Synlogic (NASDAQ:SYBX) Inc. is a clinical-stage biotechnology company pioneering the development of synthetic biotic medicines—engineered live bacterial therapies designed to treat a range of rare and severe diseases. By leveraging advances in synthetic biology and metabolic engineering, Synlogic creates genetically modified probiotic strains that perform therapeutic functions within the human body, such as metabolizing toxic compounds or modulating immune responses. The company’s platform focuses on optimizing safety, manufacturability and targeted delivery of synthetic biotics through proprietary strain design and rigorous preclinical evaluation.
The company’s lead programs include SYNB1618, an investigational therapy for phenylketonuria (PKU) that breaks down excess phenylalanine in the gastrointestinal tract, and SYNB1020, a candidate aimed at reducing ammonia levels in patients with urea cycle disorders. Synlogic is also advancing early-stage programs in nonalcoholic steatohepatitis (NASH) and immuno-oncology, where engineered strains are being evaluated for their ability to modulate host metabolic and immune pathways. Each program is supported by translational biomarker strategies and collaborative efforts with academic and industry partners.
Founded in 2013 as a spin-out from the Massachusetts Institute of Technology, Synlogic is headquartered in Cambridge, Massachusetts, with research, development and manufacturing facilities designed to support both preclinical and clinical operations. The company has conducted clinical trials across North America and Europe, and maintains collaborations with leading pharmaceutical companies to accelerate clinical development and broaden the potential applications of its synthetic biotic platform.
Synlogic is led by a management team and board of directors with deep expertise in synthetic biology, drug development and commercialization. The executive leadership brings together veterans from the biotechnology sector, along with the company’s founding scientists, to drive innovation in live microbial therapies. With a robust pipeline and strategic partnerships, Synlogic aims to establish synthetic biotics as a new therapeutic modality for patients with high unmet medical needs.
